Results 211 to 220 of about 160,066 (290)

A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing [PDF]

open access: yes, 2019
Chen, David Y.   +9 more
core   +1 more source

Impact of G‐CSF on Donor TCR Clonal Diversity and T Cell Function During Donor HSC Mobilisation

open access: yesCell Proliferation, EarlyView.
In this study, we found that G‐CSF mobilisation caused a reduction in TCR clonal diversity and down‐regulation of T‐cell function in donors. This may be one of the reasons for the low incidence of GVHD mediated by G‐CSF after allo‐HSCT. Source: Created in BioRender. Li https://BioRender.com/otownki.
Xinye Li   +14 more
wiley   +1 more source

Targeting the Menin–KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Acute leukemias characterized by a shared epigenetic dependency on the menin–KMT2A axis rely on aberrant HOX‐driven transcriptional programs that sustain leukemic self‐renewal and impair differentiation. This dependency is most evident in KMT2A‐rearranged and NPM1‐mutated acute myeloid leukemia (AML), but also extends to other HOX‐dependent ...
Antonella Bruzzese   +12 more
wiley   +1 more source

Differentiation of the mononuclear phagocyte system during mouse embryogenesis:the role of transcription factor PU.1 [PDF]

open access: yes, 1999
Browne, C M   +7 more
core  

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking   +6 more
wiley   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino   +13 more
wiley   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino   +16 more
wiley   +1 more source

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

open access: yesThe FEBS Journal, EarlyView.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy